Baricitinib prevents GvHD by increasing Tregs via JAK3 and treats established GvHD by promoting intestinal tissue repair via EGFR
Sign Up to like & getrecommendations! Published in 2021 at "Leukemia"
DOI: 10.1038/s41375-021-01360-9
Abstract: TO THE EDITOR Graft-vs-host disease (GvHD) is the major cause of non-relapse morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT) [1]. We were the first to report that pharmacologic inhibition of Janus kinases… read more here.
Keywords: vehicle control; bari; supplementary fig;
A rare association of anti-alanine-transfer RNA synthetase (anti-PL12) syndrome and sporadic inclusion body myositis
Sign Up to like & getrecommendations! Published in 2018 at "Scandinavian Journal of Rheumatology"
DOI: 10.1080/03009742.2017.1350747
Abstract: Unit of Rheumatology (DETO), Policlinico Hospital, University of Bari, Bari, Italy Department of Basic Medicine, Neuroscience and Sense Organs, Unit of Neurodegenerative Diseases, Policlinico Hospital, University of Bari, Bari, Italy Department of Basic Medicine, Neuroscience… read more here.
Keywords: medicine; hospital university; policlinico hospital; rheumatology ... See more keywords
FP025THE ROLE OF LONG NON-CODING RNAS IN THE REGULATION OF ADULT RENAL STEM/PROGENITOR CELLS (ARPCS) FUNCTIONS
Sign Up to like & getrecommendations! Published in 2018 at "Nephrology Dialysis Transplantation"
DOI: 10.1093/ndt/gfy104.fp025
Abstract: S. Simone, G. De Palma, A. Stasi, C. Curci, R. Franzin, M. Accetturo, M. Rutigliano, G. Lucarelli, M. Battaglia, A. Gallone, G. Grandaliano, G. Castellano, L. Gesualdo, Giovanni Pertosa, F. Sallustio Andrology and Kidney Transplantation… read more here.
Keywords: nephrology; bari italy; bari bari; university bari ... See more keywords
P204 Effect of baricitinib on functional impairment in RA patients with moderate disease activity and an inadequate response to conventional DMARDs
Sign Up to like & getrecommendations! Published in 2020 at "Rheumatology"
DOI: 10.1093/rheumatology/keaa111.199
Abstract: In RA, disease activity correlates with physical function and there is a link between joint damage and functional disability. In many countries, RA patients with inadequate response (IR) to MTX or other conventional DMARDs (cDMARDs)… read more here.
Keywords: eli lilly; disease activity; treatment; bari ... See more keywords
P107 Long-term efficacy of baricitinib in patients with rheumatoid arthritis with inadequate response to bDMARDs: results from RA-BEYOND up to 6.9-years of treatment
Sign Up to like & getrecommendations! Published in 2023 at "Rheumatology"
DOI: 10.1093/rheumatology/kead104.148
Abstract: Baricitinib (BARI), an oral selective Janus kinase 1/2 inhibitor, is approved for treatment of adults with moderately-to-severely active rheumatoid arthritis (RA). BARI demonstrated efficacy in patients (pts) with RA who have inadequate response to biologic… read more here.
Keywords: research; efficacy; eli lilly; bari ... See more keywords
Extracorporeal Oxygenation and Coronavirus Disease 2019 Epidemic: Is the Membrane Fail-Safe to Cross Contamination?
Sign Up to like & getrecommendations! Published in 2020 at "ASAIO Journal"
DOI: 10.1097/mat.0000000000001199
Abstract: From the *Department of Emergency and Organ Transplant (D.E.T.O.), University of Bari Aldo Moro, Bari, Italy; †Department of Cardiothoracic Surgery, Amsterdam University Medical Centers, Amsterdam, The Netherlands; ‡Department of Cardiothoracic Surgery, Heart & Vascular Centre,… read more here.
Keywords: department; bari; extracorporeal oxygenation; oxygenation coronavirus ... See more keywords
FRI0096 Durability and maintenance of efficacy following prolonged treatment with baricitinib
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.1311
Abstract: Background Baricitinib (bari) demonstrated clinical efficacy in Ph3 trials in RA patients (pts) naïve to DMARDs (RA-BEGIN1); and in RA pts with inadequate response to conventional synthetic DMARDs (RA-BEAM2 and RA-BUILD3) or biologic DMARDs (RA-BEACON4).… read more here.
Keywords: response; lilly company; eli lilly; durability ... See more keywords
AB0281 Characterization of changes in lymphocyte subsets in baricitinib-treated patients with early, dmard naÏve, rheumatoid arthritis in a phase 3 study
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.1336
Abstract: Background In RA-BEGIN (NCT01711359), baricitinib (bari), an oral Janus Kinase (JAK)1/JAK2 inhibitor, improved signs and symptoms of moderately to severely active RA in patients (pts) who had received no or limited prior csDMARD and no… read more here.
Keywords: lilly company; eli lilly; mtx; cell ... See more keywords
FRI0013 Converting patient-reported physical function outcomes scores to promis metric scores in phase 3 trials of baricitinib in rheumatoid arthritis
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.2001
Abstract: Background In patients (pts) with RA, physical function (PF) can be measured with the Health Assessment Questionnaire-Disability Index (HAQ-DI). Patient-Reported Outcomes Measurement Information System (PROMIS) was developed by the National Institutes of Health using a… read more here.
Keywords: eli lilly; lilly company; bari; physical function ... See more keywords
POS0701 LONG-TERM EFFICACY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO HAVE HAD INADEQUATE RESPONSE TO csDMARDs: RESULTS FROM RA-BEYOND UP TO 7 YEARS OF TREATMENT
Sign Up to like & getrecommendations! Published in 2022 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2022-eular.4546
Abstract: Baricitinib (BARI), an oral selective Janus kinase 1/2 inhibitor, has demonstrated efficacy in patients (pts) with rheumatoid arthritis (RA) for up to 3 years (yrs) in a long-term extension (LTE) study RA-BEYOND.1Disclose efficacy of BARI… read more here.
Keywords: lilly company; efficacy; eli lilly; bari ... See more keywords
Efficacy and drug persistence of baricitinib monotherapy is similar to combination therapy in patients with active RA: a prospective observational study
Sign Up to like & getrecommendations! Published in 2022 at "RMD Open"
DOI: 10.1136/rmdopen-2022-002674
Abstract: Background Baricitinib (BARI) is approved for the treatment of rheumatoid arthritis (RA) after failure of conventional synthetic and biologic disease modifying anti-rheumatic drugs (cs/bDMARDs) in combination with methotrexate (MTX) or as monotherapy. However, real-world data… read more here.
Keywords: bari; monotherapy; efficacy drug; drug persistence ... See more keywords